Maze Therapeutics (NASDAQ:MAZE) Hits New 52-Week High on Analyst Upgrade

Key Points

• Maze Therapeutics' share price reached a new 52-week high of $25.50, significantly up from a previous closing price of $16.02, with a trading volume of over 5 million shares.
• Analysts have given favorable ratings for the stock, with two brokers giving a "Strong Buy" rating and an average price target of $26.33.
• The company reported a quarterly earnings per share (EPS) of ($0.77), beating analyst estimates by $0.02, signaling a positive outlook.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) reached a new 52-week high on Friday after Guggenheim raised their price target on the stock from $19.00 to $34.00. Guggenheim currently has a buy rating on the stock. Maze Therapeutics traded as high as $25.50 and last traded at $24.80, with a volume of 5074476 shares. The stock had previously closed at $16.02.

A number of other equities analysts have also recently commented on the company. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright raised their target price on Maze Therapeutics from $34.00 to $50.00 and gave the company a "buy" rating in a report on Friday, September 12th. BTIG Research raised their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a report on Friday, September 12th. Finally, Wedbush began coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $32.67.

Insider Transactions at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MAZE. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth about $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in Maze Therapeutics during the 1st quarter worth approximately $45,460,000. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the 1st quarter worth approximately $45,362,000. Matrix Capital Management Company LP purchased a new position in Maze Therapeutics during the 1st quarter worth approximately $27,373,000. Finally, Alphabet Inc. purchased a new position in Maze Therapeutics during the 1st quarter worth approximately $26,561,000.

Maze Therapeutics Stock Performance

The business has a 50 day moving average of $15.67 and a 200-day moving average of $12.43.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.